iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-202 , which is the Nucleocapsid (N) protein for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties; and offers a range of process development, manufacturing, and bio analytic services. iBio, Inc. has a license agreement with University of Pittsburgh; a non-exclusive agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with RubrYc. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

iBio’s mission is to provide innovative technologies and products to help combat the global challenges of pandemics and infectious diseases.

iBio’s vision is to create an accessible and cost-effective system to produce life-saving biologics and therapies for global health challenges.

iBio has been the recipient of the French American Development Foundation Prize for Technology, the New York Life Science Innovation Award, and the Tennessee Valley Life Science Alliance Award for Innovation.